PDS Biotechnology to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference
September 22 2021 - 8:30AM
PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage
immunotherapy company developing novel cancer therapies based on
the Company’s proprietary Versamune® T-cell activating technology,
today announced that its management will present at the Cantor
Fitzgerald Virtual Global Healthcare Conference.
The presentation will provide an update on the three ongoing
PDS0101 Phase 2 clinical trials. The talk will also provide updates
on progression of two other investigational pipeline products
PDS0102 (Versamune®-TARP) and PDS0103 (Versamune®-MUC1) into human
clinical trials. The conference is taking place virtually
from September 27 - 30, 2021. Details for the presentation are as
follows:
Cantor Fitzgerald Virtual Global Healthcare
Conference:Date: Tuesday, September 28, 2021Time: 4:40 pm
EDTInvestors can register for the conference HERE.
Following the conference a webcast replay of the presentation
will be available on the Investor section of the company’s website,
PDS Biotechnology.
About PDS BiotechnologyPDS Biotech is a
clinical-stage immunotherapy company developing a growing pipeline
of cancer immunotherapies based on the Company’s proprietary
Versamune® T-cell activating technology platform. Our
Versamune®-based products have demonstrated the potential to
overcome the limitations of current immunotherapy by inducing in
vivo, large quantities of high-quality, highly potent
polyfunctional tumor specific CD4+ helper and CD8+ killer T-cells.
PDS Biotech has developed multiple therapies, based on combinations
of Versamune® and disease-specific antigens, designed to train the
immune system to better recognize diseased cells and effectively
attack and destroy them. The company’s pipeline products address
various cancers including breast, colon, lung, prostate and ovarian
cancers. To learn more, please visit www.pdsbiotech.com or follow
us on Twitter at @PDSBiotech.
About PDS0101PDS Biotech’s lead candidate,
PDS0101, combines the utility of the Versamune® platform with
targeted antigens in HPV-expressing cancers. In partnership
with Merck & Co., PDS Biotech is evaluating a combination of
PDS0101 and KEYTRUDA® in a Phase 2 study in first-line treatment of
recurrent or metastatic head and neck cancer. PDS Biotech is also
conducting two additional Phase 2 studies in advanced
HPV-associated cancers and locally advanced cervical cancer with
the National Cancer Institute (NCI) and The University of Texas MD
Anderson Cancer Center, respectively.
Forward Looking StatementsThis communication
contains forward-looking statements (including within the meaning
of Section 21E of the United States Securities Exchange Act of
1934, as amended, and Section 27A of the United States Securities
Act of 1933, as amended) concerning PDS Biotechnology Corporation
(the “Company”) and other matters. These statements may discuss
goals, intentions and expectations as to future plans, trends,
events, results of operations or financial condition, or otherwise,
based on current beliefs of the Company’s management, as well as
assumptions made by, and information currently available to,
management. Forward-looking statements generally include statements
that are predictive in nature and depend upon or refer to future
events or conditions, and include words such as “may,” “will,”
“should,” “would,” “expect,” “anticipate,” “plan,” “likely,”
“believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”,
“outlook” and other similar expressions among others.
Forward-looking statements are based on current beliefs and
assumptions that are subject to risks and uncertainties and are not
guarantees of future performance. Actual results could differ
materially from those contained in any forward-looking statement as
a result of various factors, including, without limitation: the
Company’s ability to protect its intellectual property rights; the
Company’s anticipated capital requirements, including the Company’s
anticipated cash runway and the Company’s current expectations
regarding its plans for future equity financings; the Company’s
dependence on additional financing to fund its operations and
complete the development and commercialization of its product
candidates, and the risks that raising such additional capital may
restrict the Company’s operations or require the Company to
relinquish rights to the Company’s technologies or product
candidates; the Company’s limited operating history in the
Company’s current line of business, which makes it difficult to
evaluate the Company’s prospects, the Company’s business plan or
the likelihood of the Company’s successful implementation of such
business plan; the timing for the Company or its partners to
initiate the planned clinical trials for PDS0101, PDS0203 and other
Versamune® based products; the future success of such trials; the
successful implementation of the Company’s research and development
programs and collaborations, including any collaboration studies
concerning PDS0101, PDS0203 and other Versamune® based products and
the Company’s or monitoring committees’ or other third parties’
interpretation of the results and findings of such programs and
collaborations and whether such results are sufficient to support
the future success of the Company’s product candidates; the
success, timing and cost of the Company’s ongoing clinical trials
and anticipated clinical trials for the Company’s current product
candidates, including statements regarding the timing of
initiation, pace of enrollment, significance of milestones and
completion of the trials (including our ability to fully fund our
disclosed clinical trials, which assumes no material changes to our
currently projected expenses), futility analyses, presentations at
conferences and data reported in an abstract, and receipt of
interim results, which are not necessarily indicative of the final
results of the Company’s ongoing clinical trials; any Company
statements about its understanding of product candidates mechanisms
of action and interpretation of preclinical and early clinical
results from its clinical development programs and any
collaboration studies; the acceptance by the market of the
Company’s product candidates, if approved; the timing of and the
Company’s ability to obtain and maintain U.S. Food and Drug
Administration or other regulatory authority approval of, or other
action with respect to, the Company’s product candidates; and other
factors, including legislative, regulatory, political and economic
developments not within the Company’s control, including unforeseen
circumstances or other disruptions to normal business operations
arising from or related to COVID-19. The foregoing review of
important factors that could cause actual events to differ from
expectations should not be construed as exhaustive and should be
read in conjunction with statements that are included herein and
elsewhere, including the risk factors included in the Company’s
annual and periodic reports filed with the SEC. The forward-looking
statements are made only as of the date of this press release and,
except as required by applicable law, the Company undertakes no
obligation to revise or update any forward-looking statement, or to
make any other forward-looking statements, whether as a result of
new information, future events or otherwise.
Media & Investor Relations Contact:Deanne
RandolphPDS BiotechPhone: +1 (908) 517-3613Email:
drandolph@pdsbiotech.com
Rich CockrellCG CapitalPhone: +1 (404) 736-3838 Email:
pdsb@cg.capital
PDS Biotechnology (NASDAQ:PDSB)
Historical Stock Chart
From Aug 2024 to Sep 2024
PDS Biotechnology (NASDAQ:PDSB)
Historical Stock Chart
From Sep 2023 to Sep 2024